
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bisantrene,Bisantrene DiHCl
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Race Oncology
Deal Size : $1.0 million
Deal Type : Agreement
Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220
Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : Bisantrene,Bisantrene DiHCl
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Race Oncology
Deal Size : $1.0 million
Deal Type : Agreement
